<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04962841</url>
  </required_header>
  <id_info>
    <org_study_id>Campania Nord</org_study_id>
    <nct_id>NCT04962841</nct_id>
  </id_info>
  <brief_title>Nutraceuticals and Drug Treatment in Frail Older Adults</brief_title>
  <official_title>Cognitive and Physical Impairment in Frail Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campania &quot;Luigi Vanvitelli&quot;</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Frailty is a multidimensional condition due to reserve loss leading to physical and cognitive&#xD;
      impairment that is very common in older adults; in fact, its incidence increases with age.&#xD;
      Frail older adults present a high risk of adverse events such as disability, hospitalization&#xD;
      and mortality. It is very important to check comorbidities and complications to reduce the&#xD;
      incidence of cognitive and physical impairment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Frailty is a multidimensional condition due to reserve loss leading to physical and cognitive&#xD;
      impairment that is very common in older adults; in fact, its incidence increases with age.&#xD;
      Frail older adults present a high-risk of adverse events such as disability, hospitalization&#xD;
      and mortality. It is very important to check comorbidities and complications to reduce the&#xD;
      incidence of cognitive and physical impairment; hence, clinical evaluation is the main goal&#xD;
      to get an early diagnosis and a timely treatment for cognitive impairment. Considering this&#xD;
      background, the study will investigate the effects of nutraceuticals and drug treatment on&#xD;
      cognitive impairment in frail older adults. In this scenario, global cognitive function will&#xD;
      be evaluated with Mini Mental State Examination (MMSE) and Montreal Cognitive Assessment&#xD;
      (MoCA) test and physical impairment with the Fried criteria and 5-metres gait speed test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Actual">July 22, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>July 2021</time_frame>
    <description>Global cognitive impairment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>5 metres gait speed test</measure>
    <time_frame>July 2021</time_frame>
    <description>Physical impairment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation between MMSE/MoCA and 5 metres gait speed test</measure>
    <time_frame>July 2021</time_frame>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">485</enrollment>
  <condition>Frailty</condition>
  <arm_group>
    <arm_group_label>Frail older adults treated with nutraceuticals and drugs</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Frail older adults not treated with nutraceuticals and drugs</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nutraceuticals</intervention_name>
    <description>To observe the effect on cognitive and physical impairment.</description>
    <arm_group_label>Frail older adults treated with nutraceuticals and drugs</arm_group_label>
    <other_name>empaglifozin</other_name>
    <other_name>nebivolol</other_name>
    <other_name>sertraline</other_name>
    <other_name>rivastigmine</other_name>
    <other_name>metformin</other_name>
    <other_name>ramipril</other_name>
    <other_name>amlodipine</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Frail older adults.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age &gt; 65 years;&#xD;
&#xD;
          -  a frailty status.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt; 65 years.&#xD;
&#xD;
          -  no frailty status.&#xD;
&#xD;
          -  left ventricular ejection fraction &lt;25%, with previous myocardial infarction or&#xD;
             previous PPCI or/and coronary by-pass grafting.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Pasquale Mone, MD</last_name>
    <phone>+393384423895</phone>
    <email>pasquale.mone@unicampania.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antonella Pansini, MD</last_name>
    <phone>+393397189467</phone>
    <email>apansini@aslavellino.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pasquale Mone</name>
      <address>
        <city>Naples</city>
        <state>It</state>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonella Pansini, MD</last_name>
      <phone>+393397189467</phone>
      <email>apansini@aslavellino.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Cortes-Canteli M, Iadecola C. Alzheimer's Disease and Vascular Aging: JACC Focus Seminar. J Am Coll Cardiol. 2020 Mar 3;75(8):942-951. doi: 10.1016/j.jacc.2019.10.062. Review.</citation>
    <PMID>32130930</PMID>
  </reference>
  <reference>
    <citation>Afilalo J, Alexander KP, Mack MJ, Maurer MS, Green P, Allen LA, Popma JJ, Ferrucci L, Forman DE. Frailty assessment in the cardiovascular care of older adults. J Am Coll Cardiol. 2014 Mar 4;63(8):747-62. doi: 10.1016/j.jacc.2013.09.070. Epub 2013 Nov 27. Review.</citation>
    <PMID>24291279</PMID>
  </reference>
  <reference>
    <citation>Jung HW, Baek JY, Jang IY, Guralnik JM, Rockwood K, Lee E, Kim DH. Short Physical Performance Battery as a crosswalk between frailty phenotype and deficit-accumulation frailty index. J Gerontol A Biol Sci Med Sci. 2021 Mar 29. pii: glab087. doi: 10.1093/gerona/glab087. [Epub ahead of print]</citation>
    <PMID>33780526</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 10, 2021</study_first_submitted>
  <study_first_submitted_qc>July 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campania &quot;Luigi Vanvitelli&quot;</investigator_affiliation>
    <investigator_full_name>Pasquale Mone</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>frailty</keyword>
  <keyword>cognitive impairment</keyword>
  <keyword>physical impairment</keyword>
  <keyword>older adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Frailty</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
    <mesh_term>Rivastigmine</mesh_term>
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

